The Drug-Induced Respiratory Disease Website and App

COVID19 (SARS-CoV2) vaccination/vaccine

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I - Interstitial/parenchymal lung disease

I.a

Pneumonitis (ILD)

I.b

Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I.c

Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I.z

Progression, acceleration or exacerbation of preexisting ILD/fibrosis

I.ae

Radiation recall pneumonitis

I.az

Unilateral interstitial lung disease

I.bd

Exacerbation of preexisting/underlying RA-ILD

II - Pulmonary edema - Acute lung injury - ARDS

II.b

Pulmonary edema, cardiogenic

II.e

ARDS - Acute lung injury

III - Pulmonary/alveolar./airway hemorrhage/bleeding

III.a

Alveolar hemorrhage (AH), diffuse AH (DAH)

III.m

Coagulopathy

IV - Airway involvement

IV.a

Bronchospasm - Wheezing - Asthma

IV.c

Exacerbation or deterioration of preexisting asthma

VII - Pulmonary vasculopathy

VII.a

Pulmonary embolism - Venous thrombosis/thromboembolism

VII.b

Pulmonary arterial hypertension

VII.ab

Pulmonary infarction

IX - Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.r

Myasthenia gravis - Myasthenic-like syndrome

IX.y

A flare or relapse of preexisting myasthenia gravis

IX.ab

Guillain-Barré (or GB-like) syndrome (w/wo ARF)

X - Systemic/Distant conditions, syndromes and reactions

X.b

Antiphospholipid antibodies w/wo the APL syndrome

X.d

Lupus - Lupus syndrome (see also Vd)

X.f

Anaphylaxis-Anaphylactoid reaction (can be fatal)

X.h

Protracted, prolonged anaphylaxis

X.j

Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

X.l

Myopathy-Myositis-Polymyositis (see also under Xba)

X.o

Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X.u

Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

X.al

Polyarteritis nodosa-like condition

X.bg

Anti-Jo-1 syndrome

X.bh

A flare of preexisting immune-mediated systemic/rheumatic disease

X.bi

IgA vasculitis

X.bk

Anti Jo1 syndrome

XI - Miscellaneous

XI.b

Chest pain (acute or subacute), lone or prominent

XII - Cardiovascular involvement / toxicity

XII.a

Left or biventricular dysfunction/failure

XII.c

Pericardial effusion (w/wo tamponade)

XII.d

Myocarditis (can be fulminant)

XII.e

Relapse of previously diagnosed myocarditis

XII.f

Takotsubo (stress) cardiomyopathy

XII.h

Coronary artery disease (acute) - Myocardial ischemia/infarction

XII.i

Eosinophilic myocarditis

XII.l

Constrictive pericarditis - Pericardial thickening

XII.n

Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII.r

Pericarditis (see also under XIIc)

XII.u

Cardiac- cardiorespiratory/pulmonary arrest

XII.ak

Cardiotoxicity

XII.bi

Myopericarditis (see under XIIc/d/g)

XVI - Imaging

XVI.b

Imaging: Ground-glass opacities (GGO) / shadowing

XVI.c

Imaging: A mosaic pattern of attenuation

XVI.ba

Imaging: Asymmetrical, predominantly unilateral involvement

XVIII - Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.a

BAL: An excess proportion of lymphocytes

XVIII.c

BAL: An excess proportion of eosinophils

XIX - Pathology

XIX.a

Path: NSIP-cellular pattern (see also Ia, Ib)

XIX.d

Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)